P759: Understanding how patients with moderate-to-severe Crohn’s disease describe the spectrum of bowel urgency definitions: Results from qualitative researchECCO'24Year: 2024
Authors: Dubinsky, M.C.(1)*;Hunter Gibble, T.(2);Stassek, L.(3);Harding, G.(3);Stefan, M.(3);Fikre, T.(3);Potts Bleakman, A.(4);Moses, R.(4);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States;(2)Eli Lilly and Company, Value- Evidence- and Outcomes, Indianapolis, United States;(3)Evidera, Evidera, Bethesda, United States;(4)Eli Lilly and Company, Medical Affairs, Indianapolis, United States;
P760: Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: A final report of effectiveness and safety dataECCO'24Year: 2024
Authors: Matsuoka, K.(1)*;Motoya, S.(2);Yamamoto, T.(3);Matsuura, M.(4);Fujii, T.(5);Shinzaki, S.(6);Mikami, Y.(7);Arai, S.(8);Oshima, J.(9);Endo, Y.(9);Yuasa, H.(9);Hoshi, M.(8);Sato, K.(9);Hisamatsu, T.(4);
(1)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Chiba, Japan;(2)Sapporo-Kosei General Hospital, Inflammatory Bowel Disease Center, Hokkaido, Japan;(3)Yokkaichi Hazu Medical Center, Department of Surgery and IBD Center, Yokkaichi Mie, Japan;(4)Kyorin University, Department of Gastroenterology and Hepatology, Mitaka Tokyo, Japan;(5)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(6)Hyogo Medical University, Division of Gastroenterology- Faculty of Medicine, Nishinomiya Hyogo, Japan;(7)Keio University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan;(8)-, Pfizer Japan Inc, Tokyo, Japan;(9)-, Pfizer R&D Japan, Tokyo, Japan;
P761: Clinical efficacy and durability of subcutaneous infliximab in patients with moderate-to-severe inflammatory bowel disease : a real-world data from a Korean multicentre prospective cohort studyECCO'24Year: 2024
Authors: Kim, K.(1)*;Hong, S.N.H.(2);Kang, S.B.K.(3);Lee, K.M.(4);Koo, J.S.K.(5);Jung , Y.(6);Lee, B.J.L.(7);Yoon, H.Y.(8);Kim, H.W.(9);Lim, Y.J.(10);Lee, H.S.(11);Lee, Y.J.(12);Lee , J.(13);Lee, C.K.(14);Moon, J.M.(15);Shin, S.Y.(16);Seo , J.(17);Choi , C.H.(17);
(1)Chung-Ang University Hospital, Department of gastroenterology, Seoul, Korea- Republic Of;(2)Samsung Medical Center- Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea- Republic Of;(3)Daejeon St. Mary’s Hospital- The Catholic University, Division of Gastroenterology- Department of Internal medicine, Daejeon St. Mary’s Hospital, Korea- Republic Of;(4)St. Vincent@E@s Hospital- College of Medicine- The Catholic University of Korea, Department of Internal Medicine, Suwon, Korea- Republic Of;(5)Korea University College of Medicine, Department of internal medicine, Ansan, Korea- Republic Of;(6)Soonchunhyang University College of Medicine, Department of Internal Medicine, Cheonan, Korea- Republic Of;(7)Korea University College of Medicine, Department of Internal Medicine, Seoul, Korea- Republic Of;(8)Seoul National University Bundang Hospital, Department of Internal Medicine, Seongnam, Korea- Republic Of;(9)Pusan National University Yangsan Hospital- Pusan National University College of Medicine, Department of Internal Medicine, Yangsan, Korea- Republic Of;(10)Dongguk University Ilsan Hospital, Department of Internal Medicine, Goyang, Korea- Republic Of;(11)Kyungpook National University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(12)Keimyung University School of Medicine-, Department of Internal Medicine, Daegu, Korea- Republic Of;(13)Chosun University College of Medicine, Department of Internal Medicine, Gwangju, Korea- Republic Of;(14)Kyung Hee University School of Medicine, Department of internal medicine, Seoul, Korea- Republic Of;(15)Chung-Ang University Gwangmyeong Hospital, Department of internal mediciine, Gwangmyeong, Korea- Republic Of;(16)Chung-Ang University Gwangmyeong Hospital, Internal medicine, Gwangmyeong, Korea- Republic Of;(17)Chung-Ang University Hospital, Internal medicine, Seoul, Korea- Republic Of;
P762: Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration studyECCO'24Year: 2024
Authors: Kim, S.J.(1)*;Kim, D.H.(2,3);Park, S.H.(3,4);Kim, K.O.(3,5);Lee, Y.J.(3,6);Song, E.M.(3,7);Kim, E.S.(3,8);Lee, H.S.(8);An, Y.K.(9,10);Begun, J.(9,10);Ruddick-Collins, L.(10,11);Fernandes, R.(9);Liu, J.(12);Cao, Q.(12);Kobayashi, T.(13);Wei, S.C.(14);
(1)Chosun University Hospital, Division of Gastroenterology- Department of Internal Medicine, Gwangju, Korea- Republic Of;(2)Chonnam National University, Division of Gastroenterology- Department of Internal Medicine, Gwangju, Korea- Republic Of;(3)Korean Association for the Study of the Intestinal Diseases, IBD Research Group, Seoul, Korea- Republic Of;(4)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;(5)Yeungnam University Hospital, Division of Gastroenterology- Department of Internal Medicine, Daegu, Korea- Republic Of;(6)Keimyung University Hospital, Division of Gastroenterology- Department of Internal Medicine, Daegu, Korea- Republic Of;(7)Ewha Womans University Seoul Hospital, Division of Gastroenterology- Department of Internal Medicine, Seoul, Korea- Republic Of;(8)Kyungpook National University Hospital, Division of Gastroenterology- Department of Internal Medicine, Daegu, Korea- Republic Of;(9)Mater Hospital, Department of Gastroenterology, Brisbane, Australia;(10)ANZIBDC, Australia New Zealand IBD Consortium, Brisbane, Australia;(11)University of Queensland, Mater Research Institute, Brisbane, Australia;(12)Zhejiang Chinese Medical University, School of Life Science, Hangzhou, China;(13)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(14)National Taiwan University Hospital- National Taiwan University, Department of Internal Medicine-, Taiwan, Taiwan;
P763: Rare and severe adverse events in pediatric inflammatory bowel disease: identification of safety signals through the international prospective PIBD-SETQuality Safety RegistryECCO'24Year: 2024
Authors: Klomberg, R.(1)*;Hellendoorn, A.(1);Kemos, C.(2);Rizopoulos, D.(3);Ruemmele, F.(4);Croft, N.(2);de Ridder, L.(1);
(1)Erasmus MC - Sophia Children@E@s Hospital, Paediatric Gastroenterology, Rotterdam, The Netherlands;(2)Barts and the London School of Medicine- Queen Mary University of London, Centre for Immunobiology- Blizard Institute, London, United Kingdom;(3)Erasmus Medical Center, Department of Epidemiology, Rotterdam, The Netherlands;(4)Université Paris Descartes- Sorbonne Paris Cité- APHP- Hôpital Necker Enfants Malades, Department of Pediatric Gastroenterology, Paris, France;PIBD-SETQuality Safety Registry collaborative group
P764: Darvastrocel in Treatment of 152 Patients with Perianal Crohn@E@s Disease - Observational StudyECCO'24Year: 2024
Authors: Serclova, Z.(1)*;Tremerova, A.(2);Ryska, O.(3);Zuskova, P.(4);Lengalova, M.(4);Vlkova, K.(5);
(1)Surgery, IBD Center Iscare- Surgical Departement- University Hospital- Kralovske Vinohrady- Prague, Praha 2 - Vinohrady, Czech Republic;(2)ISCARE, IBD centrum, Prague, Czech Republic;(3)Royal Lancaster Infirmary- UHMBT, Surgical, Lancaster, United Kingdom;(4)NH Hospital, Surgical, Horovice, Czech Republic;(5)ISCARE, IBD Center, Prague, Czech Republic;
P765: A Novel Monoclonal Antibody Drug Candidate SPY001 Targeting Integrin ɑ4β7 for the Treatment of IBD Demonstrates Prolonged Half-Life in Non-Human PrimatesECCO'24Year: 2024
Authors: Zhu, E.(1);Rios, D.(2);Vaz, R.(3);Friedman, J.(4)*;Nguyen, D.(5);Spencer, A.(6);Oh, J.(2);Shaheen, H.(7);
(1)Paragon Therapeutics, Biotherapeutics Discovery, Waltham- MA, United States;(2)Paragon Therapeutics, Biology, Waltham- MA, United States;(3)Paragon Therapeutics, Program and Alliance Management, Waltham- MA, United States;(4)Spyre Therapeutics, Clinical Development, Ardmore, United States;(5)Spyre Therapeutics, Clinical Development, Waltham- MA, United States;(6)Spyre Therapeutics, Nonclinical Development, Waltham- MA, United States;(7)Paragon Therapeutics, Research, Waltham- MA, United States;
P766: No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPAREECCO'24Year: 2024
Authors: Vieujean, S.(1)*;Desseaux, K.(2);Laharie, D.(3);Satsangi, J.(4);Ding, N.(5);Siegmund, B.(6);D’Haens, G.(7); Picon, L.(8);Bossuyt, P.(9);Vuitton, L.(10);Irving, P.(11);Viennot, S.(12);Lamb, C.A.(13);Pollok, R.(14);Baert, F.(15);Nachury, M.(16);Fumery, M.(17);Gilletta, C.(18);Resche-Rigon, M.(19);Bouhnik, Y.(20);Colombel, J.F.(21);Hertervig, E.(22);Louis, E.(23);
(1)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(2)Hôpital Saint-Louis, ECSTRRA - CRESS UMR1153- INSERM and SBIM- AP-HP, Paris, France;(3)Hôpital Haut-Lévêque– Université de Bordeaux, Service d’Hépatogastroentérologie et oncologie digestive CHU de Bordeaux, Bordeaux, France;(4)John Radcliffe Hospital, Translational Gastroenterology Unit- Nuffield Department of Medicine, Oxford, United Kingdom;(5)St Vincent@E@s Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(6)Universitätsmedizin Berlin, Medical Department- Division of Gastroenterology- Infectious Diseases and Rheumatology- Charité, Berlin, Germany;(7)Amsterdam University Medical Centres, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)Hôpital Trousseau, Hépato-Gastro-Onco-Entérologie, Tours, France;(9)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(10)Besançon Univeristy Hospital, Department of Gastroenterology-, Besançon, France;(11)Guy@E@s and St Thomas@E@ NHS Foundation Trust, IBD Unit- Department of Gastroenterology, London, United Kingdom;(12)University Hospital of Caen, Department of Gastroenterology, Caen, France;(13)Newcastle upon Tyne Hospitals NHS Foundation Trust- Royal Victoria Infirmary, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom;(14)St Georges University Hospital, Gastroenterology, London, United Kingdom;(15)AZ Delta, Department of Gastroenterologie, Roeselare, Belgium;(16)University of Lille- Inserm- CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation-, Lille, France;(17)University Hospital of Amiens, Department of Gastroenterology, Amiens, France;(18)University Hospital of Toulouse Rangueil, Department of Gastroenterology and Pancreatology, Toulouse, France;(19)Hôpital SaintLouis, Université de Paris- ECSTRRA - CRESS UMR1153- INSERM and SBIM- AP-HP, Paris, France;(20)Beaujon Hospital- APHP- Paris Cité University, Department of Gastroenterology, Clichy, France;(21)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(22)Skåne University Hospital, Department of Gastroenterology, Lund, Sweden;(23)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;GETAID and the SPARE-Biocycle research group
P767: Pharmacokinetics of subcutaneous infliximab induction and maintenance in patients with moderate-to-severely active Crohn’s diseaseECCO'24Year: 2024
Authors: AnjieMD, S.(1)*;Mâthot, R.A.A.(2);Gecse, K.B.(1);D@E@Haens, G.R.A.M.(1);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam, The Netherlands;
P768: Appropriateness of small molecule agents for patients with IBD of childbearing age – a RAND appropriateness panelECCO'24Year: 2024
Authors: Selinger, C.P.(1)*;Laube, R.(2);Fraser, A.(3);Headley, K.(4);Kent, A.(5);Kok, K.(6);Lee, V.(4);Limdi, J.(7);Ludlow, H.(8);Rees, F.(9);Sagar, N.(10);Walker, E.(4);
(1)St James@E@ University Hospital, Gastroenterology, Leeds, United Kingdom;(2)Macquarie University Hospital, Gastroenterology, Sydney, Australia;(3)University Hospitals of Bristol, Gastroenterology, Bristol, United Kingdom;(4)Patient representative, Patient representative, Leeds, United Kingdom;(5)Kings College Hospital, Gastroenterology, London, United Kingdom;(6)Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(7)Northern Care Alliance, Gastroenterology, Manchester, United Kingdom;(8)University Health Board Cardiff and Vale, Gastroenterology, Cardiff, United Kingdom;(9)University Hospital Sussex NHS Trust, Gastroenterology, Brighton, United Kingdom;(10)Walsall Healthcare NHS Trust, Gastroenterology, Walsall, United Kingdom;
P769: Impact of discontinuation of anti-TNF therapy: A long term follow-up data of risks and predictors relapse in a large Indian cohortECCO'24Year: 2024
Authors: Banerjee, R.(1)*;Pal, P.(1);Mekala, D.(1);Raghunathan, N.(1);Joshi, V.(1);Akki, Y.(1);Patel, R.(1);Godbole, S.(1);Valluri, S.(1);Nagasuri, P.(1);Haridas, A.(1);
(1)Asian Institute of Gastroenterology, IBD Centre, Hyderabad, India;
P770: Proactive Infliximab monitoring improves the rates of transmural remission in Crohn’s disease – a propensity score matched analysisECCO'24Year: 2024
Authors: Fernandes, S.R.(1,2,3);Tubal Bronze, S.M.(1,2)*;Saraiva, S.(1,3);Bernardo, S.(1,3);Gonçalves, A.(1,3);Moura Santos, P.(1,2,3);Valente, A.(1);Correia, L.(1,2,3);Cortez-Pinto, H.(1,2);Magro, F.(3,4,5,6,7);
(1)Centro Hospitalar Universitário Lisboa Norte EPE, Serviço de Gastrenterologia e Hepatologia, Lisbon, Portugal;(2)Faculdade de Medicina da Universidade de Lisboa, Clinica Universitária de Gastrenterologia, Lisbon, Portugal;(3)Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii, Porto, Portugal;(4)São João Hospital University Center, Gastroenterology Department, Porto, Portugal;(5)Faculty of Medicine- University of Porto, Department of Biomedicine- Unit of Pharmacology and Therapeutics, Porto, Portugal;(6)Faculty of Medicine- University of Porto, Centre for Health Technology and Services Research- Health Research Network CINTESIS@RISE, Porto, Portugal;(7)São João Hospital University Center, Clinical Pharmacology Unit, Porto, Portugal;
P771: Comparing obstructive symptoms and dietary restrictions with Crohn@E@s disease stricture severityECCO'24Year: 2024
Authors: Saunders , B.(1);Lesack , K.(1);Rosentreter , R.(1);Macci , A.(1);Novak , K.(1);Ma , C.(1);Kaplan , G.(1);Ingram , R.J.(1);Seow , C.(1);Panaccione- , R.(1);Lu , C.(1)*;
(1)University of Calgary, Medicine- Division of Gastroenterology and Hepatology, Calgary, Canada;
P772: Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trialECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Feagan, B.G.(2,3);Vermeire, S.(4);Danese, S.(5,6);Vyncke, V.(7);Faes, M.(8);Oortwijn, A.(9);Peyrin-Biroulet, L.(10,11,12,13,14,15);
(1)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)Alimentiv Inc., Senior Scientific Director, London ON, Canada;(3)Western University, Division of Gastroenterology- London Health Sciences Centre, London ON, Canada;(4)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)IRCCS Hospital San Raffaele, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(6)Vita-Salute San Raffaele University, Department of Gastroenterology, Milan, Italy;(7)Galapagos NV, Medical Affairs, Mechelen, Belgium;(8)Galapagos NV, Biostatistics, Mechelen, Belgium;(9)Galapagos B.V., Medical Affairs, Leiden, The Netherlands;(10)Nancy University Hospital, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(11)McGill University Health Centre, Division of Gastroenterology and Hepatology, Montreal QC, Canada;(12)Paris IBD Center, Ambroise Paré – Hartmann Private Hospital Group, Neuilly-sur-Seine, France;(13)Nancy University Hospital, FHU Curing and Preventing IMID CURE, Vandœuvre-lès-Nancy, France;(14)Nancy University Hospital, INFINY Institute, Vandœuvre-lès-Nancy, France;(15)University of Lorraine, Inserm- NGERE, Nancy, France;
P774: Less combination therapy and more fistulotomy in perianal fistulizing Crohn’s disease in the elderlyECCO'24Year: 2024
Authors: Arjafallah Goulet, O.(1)*;Brochard, C.(2);Atienza, P.(1);Siproudhis, L.(2);Etienney, I.(1);
(1)GH Diaconesses Croix Saint Simon Hospital, Proctology, Paris, France;(2)CHU Pontchaillou, Gastroenterology and proctology, Rennes, France;
P775: Efficacy and safety of risankizumab in children with Crohn’s disease: A preliminary reportECCO'24Year: 2024
Authors: Spencer, E.(1);Stein, R.(2);Shalem, T.(3);Zifman, E.(4);Dubinsky, M.(5);Lev Tzion, R.(6);Turner, D.(6);Assa, A.(7)*;
(1)Mount Sinai Hospital- New York City- NY- USA., Division of Gastroenterology- Hepatology and Nutrition-, New York City- NY, United States;(2)The Children@E@s Hospital of Philadelphia- Philadelphia- PA.- USA, Division of Gastroenterology- Hepatology- and Nutrition, Philadelphia- PA, United States;(3)Shamir Assaf Harofeh Medical Center and the Faculty of Medicine- Tel Aviv University- Israel, Pediatric Gastroenterology Institute, Zeriffin, Israel;(4)Meir Medical Center- Kfar-Saba and the Faculty of Medicine- Tel Aviv University- Israel, The Pediatric Gastroenterology Unit-, Kfar-Saba, Israel;(5)Mount Sinai Hospital- New York City- NY- USA., Division of Gastroenterology- Hepatology and Nutrition, New York City- NY, United States;(6)Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Jerusalem- Israel, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(7)Shaare Zedek Medical Center- The Hebrew University- Jerusalem Israel, The Juliet Keidan institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;
P776: A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-world Clinical Practice in China: Interim Analysis of Safety resultsECCO'24Year: 2024
Authors: Zheng, C.(1);Chen, B.(2);Yu, J.(3); Wang, X.(4);Li , L.(2);Hu, Y.(5); Xie, L.(5); Liu, M.(6);Chen, M.(2)*;
(1)Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang, China;(2)The First Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(3)The First Affiliated Hospital of Shantou University Medical College, Department of Gastroenterology, Guangzhou, China;(4)The Third Xiangya Hospital of Central South University, Department of Gastroenterology, Changsha, China;(5)Takeda China International Trade Co. Ltd, Medical, Shanghai, China;(6)Takeda Development Center Asia, Biostatistics, Beijing, China;
P777: Is the long-term Budesonide use have any influence on Bone Mineral Density in Inflammatory Bowel Diseases?ECCO'24Year: 2024
Authors: Eskazan, T.(1)*;Durcan, E.(2);Bakkaloglu, O.K.(1);Kurt, E.A.(1);Onal, U.(1);Hatemi, İ.(1);Erzin, Y.Z.(1);Celik, A.F.(1);
(1)I.U.C- Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;(2)I.U.C. Cerrahpasa Medical Faculty, Endocrinology, Istanbul, Turkey;
